This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
The proportion of available on-patent drugs covered in low copay tiers varied by insurance type, with the lowest proportion being in Medicare plans.
Shifting physician revenue from drug sales to cognitive services for mature pathways providers did not affect practice behavior in this payer-sponsored Oncology Medical Home.
Examining the financial impact that patient assistance programs and the 340B Drug Pricing Program have on improving medication cost.
Patients using mail order pharmacies have lower healthcare utilization, but somewhat less laboratory monitoring of persistent medications and slightly higher contraindicated medication use.